Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting-Reference-Cited by-同舟云学术

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Published:2017-05-04 Issue:27 Volume:8 Page:43653-43661
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Dougherty Brian A.¹,Lai Zhongwu¹,Hodgson Darren R.²,Orr Maria C.M.³,Hawryluk Matthew⁴,Sun James⁴,Yelensky Roman⁴,Spencer Stuart K.⁵,Robertson Jane D.⁵,Ho Tony W.⁶,Fielding Anitra⁷,Ledermann Jonathan A.⁸,Barrett J. Carl¹

Affiliation:

1. Innovative Medicines and Early Development, Oncology, AstraZeneca, Waltham, MA, USA

2. Innovative Medicines and Early Development, Oncology, AstraZeneca, Cambridge, UK

3. Personalized Healthcare and Biomarkers, AstraZeneca, Cambridge, UK

4. Foundation Medicine, Inc., Cambridge, MA, USA

5. Oncology Global Medicines Development, AstraZeneca, Cambridge, UK

6. Oncology Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA

7. Oncology Global Medicines Development, AstraZeneca, Macclesfield, UK

8. UCL Cancer Institute, London, UK

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report;Gynecologic Oncology;2024-11

2. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis;Expert Review of Anticancer Therapy;2024-01-04

3. Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology;Current Molecular Medicine;2023-11-01

4. Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer;International Journal of Molecular Sciences;2023-07-18

5. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort;Diagnostics;2023-05-29